FY26 was a record year for Redenlab. Before setting out the numbers, it’s worth restating what hasn’t changed since we founded the company: a commitment to rigorous, clinically valid science, a focus on the patients whose data we are trusted to collect, measure and interpret, and seamless deployment into complex clinical trial environments. I say that not as a preamble but because it’s the actual explanation for the year’s results, in a field where sponsors are applying increasing scrutiny to endpoints, contract growth follows scientific credibility and successful operational delivery.
A record year
We closed the year with record revenue, up more than three fold on the prior year, and an operating margin that continues to allow us to reinvest in talent and technology. We continue to take a long-term view of the business, enabled by a capital structure that has remained entirely owned by the management team, with no third-party funding since inception. That steady, patient approach to building, applied at a larger scale than we have operated at before, has compounded over time to deliver both this year’s results and the platform we are building for what comes next.
Behind those headline figures is also a more diversified business than we have run previously. We delivered work across 17 active projects this year — eight of them with sponsors extending programs already underway, the figure I am most proud of: new contracts demonstrate market interest, but sponsors returning to expand existing programs demonstrate trust in our underlying science and delivery capability. We worked across the full clinical development pathway, from Phase I through Phase IV, with global pharmaceutical companies, biotech innovators and academic research groups. Our clinical work deepened in the indications we are best known for, ALS, hereditary ataxias and paediatric neurological disorders, and this year we extended our work further into lysosomal disorders.
Recognition tied to the science
We also continued our work under the CUREator+ Dementia & Cognitive Decline program. This is a competitive, government backed initiative led by Australia’s Medical Research Future Fund, to accelerate innovations aimed at earlier, more accurate detection of dementia and cognitive decline. Redenlab was one of them, and the funding supports our continued work applying speech-based biomarker methods to pre-screening and prediction of cognitive decline and blood biomarker status.
FY27: forward visibility
We expect to almost double revenue again in FY27, underpinned by contracts already signed with several of the world’s largest pharmaceutical companies. No forward pipeline is realised until it is delivered, but the visibility we have into next year is the clearest we have had, and it is a direct consequence of the scientific standard we hold our work to.
Clinical leadership and published research
This year we welcomed Dr Gustavo Noffs MD/PhD as Chief Medical Officer, who brings a wealth of experience as an ENT surgeon, adding further clinical depth to the team responsible for our scientific and regulatory work. We also have a new product to introduce to the market shortly — detail to follow in a separate update. Our publication record continued to grow as well, including new research connecting blood based biomarkers to voice-derived outcome measures in AD and speech work in Parkinsons, MCI and ALS. Each new publication adds to the evidence base this company was built on: speech is a clinical endpoint in its own right, and we are now expanding our work to validate it against other clinically accepted signals of disease.
Market context
The environment around this work continues to support it. Investment and regulatory attention directed at CNS clinical trials continue to increase, with analysts estimating the neurology clinical trials market at roughly US$9 billion by 2030, with the broader digital biomarkers market growing faster still, toward US$17 billion at close to 20% annual growth. Sponsors are under genuine pressure to identify endpoints that are objective and less burdensome for patients than traditional clinician rated scales, and voice based measures are being adopted not only as a data source but as a validated endpoint and disease progression indicator in their own right.
The sector also continued to consolidate this year: Signant Health’s acquisition of Ametris, combining wearable derived measures with established eCOA technology, is a further indication that digital outcome measurement is being treated as core clinical trial infrastructure, and we wish our friends at Ametris and Signant the very best on their new journey.
What’s ahead
This combination of clinical results, sponsor retention and market movement has generated increasing strategic interest in Redenlab, and we continue to carefully vet new partnership opportunities that will ultimately enable our patients to live better with these debilitating diseases.
If you are planning a CNS trial and would like to discuss how our platform and clinical expertise could support it, from protocol design through to regulatory-ready evidence, please get in touch.
– Adam
For media inquiries, please contact:
Gloria Macan
Chief Marketing Officer
Redenlab
Gmacan@redenlab.com
About Redenlab:
Redenlab is a leading techbio company specialising in speech analysis and linguistic assessment tools. With a mission to enhance decision-making in clinical trials and healthcare research, Redenlab leverages leading knowledge in communication and technology to measure and analyse speech patterns, providing valuable insights into neurological conditions. Their innovative solutions are paving the way for improved
monitoring and diagnostics, personalised treatment plans, and transformative advancements in neuroscience research.
